Hello everyone,

The paper that I am going to present to you is:

“Cyclin D-CDK4 kinase destabilizes PD-L1 via Cul3SPOP to control cancer immune surveillance “

Published: 16 November 2017. Nature Article.

As a summary,

Cancer treatments that target immune checkpoints, such as programmed cell death protein 1 (PD-1) and its ligand PD-L1, is highly crucial in multiple tumour types. The cell cycle is very important in cancer as cancers development and progression are usually linked to a series of changes in the activity of cell cycle regulators including cyclin-dependent kinases (CDKs), cyclins, and cyclin-dependent kinase inhibitors (CKIs).

Provided results in this study show that PD-L1 protein abundance is regulated by cyclin D–CDK4. Hence they suggest a complementary molecular mechanism for regulating PD-L1 protein stability by combining treatment with CDK4/6 inhibitors and PD-1/PD-L1 immune checkpoint blockade to tumour regression.

Web address:

https://www.nature.com/articles/nature25015

These results will be described in the Saturday paper presentation.

Best Regards,

Payam